Incyte Corporation

This completed Phase 3 trial compared three different drug combinations for people with advanced head and neck cancer that had returned or spread. Researchers tested two newer immunotherapy approaches (pembrolizumab alone and with epacadostat) against a standard chemotherapy comb…

This study tested a cream called ruxolitinib for people with vitiligo affecting their genital skin. Forty-nine participants applied the cream twice daily for up to 48 weeks. The main goal was to see if the treatment could make the vitiligo much less noticeable or no longer notice…

This Phase 3 study tested an oral medication called povorcitinib for people with moderate to severe hidradenitis suppurativa (HS), a chronic, painful skin condition. The 619 participants took either the drug or a placebo for 12 weeks, with many continuing for an additional 42 wee…

This study tested whether a new oral medication called povorcitinib could help adults with chronic spontaneous urticaria (CSU), a condition causing persistent hives and itching that doesn't respond well to standard antihistamines. Researchers compared different doses of the drug …

This study tested whether adding the drug ruxolitinib to standard chemotherapy could help children with a particularly aggressive form of acute lymphoblastic leukemia (ALL). It involved 171 children and young adults (ages 1-21) who had specific genetic markers that make their can…

This study tested whether a cream containing ruxolitinib could help adults with moderate atopic dermatitis (eczema) who had not gotten enough relief from common prescription creams like corticosteroids. The trial involved 241 participants and compared the active cream to a placeb…

This study tested an experimental drug called pemigatinib in 47 patients with rare blood cancers caused by a specific genetic change (FGFR1 rearrangement). These patients had either relapsed after previous treatments like stem cell transplants or weren't candidates for those trea…

This study tested whether adding the drug itacitinib to standard steroid treatment works better for controlling acute graft-versus-host disease (GVHD) in people who recently had a stem cell transplant. It involved 439 participants who developed moderate to severe GVHD. The goal w…

This study tested whether adding a new drug called itacitinib to an existing lung cancer medication (osimertinib) is safe and effective. It involved 59 adults with advanced non-small cell lung cancer that had specific genetic changes (EGFR and T790M mutations) and had stopped res…

This large, completed Phase 3 trial tested whether adding a new immunotherapy drug (retifanlimab) to standard chemotherapy could better control advanced anal cancer that cannot be removed by surgery. The study involved 308 adults worldwide who had not received prior chemotherapy …

This Phase 3 clinical trial tested an oral medication called povorcitinib for people with moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin condition. The study involved 608 participants who had not responded well to previous treatments. Over 12 weeks,…

This study tested a combination of three immunotherapy drugs for people with advanced melanoma, a serious skin cancer. The main goals were to find safe doses and see if the treatment could shrink tumors, especially in patients whose cancer had stopped responding to standard immun…

This study tested a drug called itacitinib for people with a serious bone marrow cancer called myelofibrosis who had already tried other standard treatments. The main goals were to find a safe dose and see if the drug could reduce spleen size and improve symptoms. Only four peopl…

This early-stage study tested a new drug called INCA32459 in 46 people with advanced cancers that had stopped responding to standard treatments. The main goal was to find a safe dose and see how the body processes the drug. Researchers also looked for early signs that the drug mi…

This study tested whether a cream containing ruxolitinib could safely reduce severe itch and improve skin lesions in people with prurigo nodularis, a chronic skin condition. Over 200 participants applied either the active cream or a placebo cream for 12 weeks, followed by an exte…

This study tested a cream called ruxolitinib to see if it safely reduces severe itch and improves skin lesions in people with prurigo nodularis, a chronic skin condition. 190 participants with intense, long-lasting itch applied the cream or a placebo for 12 weeks, followed by an …

This early-stage study aimed to understand how a new drug candidate, INCB099280, is processed by the body. Five healthy male volunteers took a single, specially labeled oral dose. Researchers then carefully measured how much of the drug was absorbed, how long it stayed in the bod…

This early-stage study aimed to understand how three common types of medications—an antifungal, an antibiotic, and heartburn drugs—affect the body's processing of an experimental drug called INCB161734. It involved 63 healthy adult volunteers who took the experimental drug alone …

This early-stage study tested a new oral drug called INCB160058 in healthy adults to check its safety and see how the body processes it. Researchers gave single doses to 137 healthy volunteers to monitor for side effects and measure drug levels in the blood. The study also examin…

This study tested a new method using tiny needles to collect fluid from just under the skin. It involved 20 people, both healthy volunteers and those with atopic dermatitis (eczema). The goal was to see if this method works well and is comfortable, to help researchers better unde…

This early-stage study aimed to understand how the body absorbs, processes, and eliminates an experimental drug called INCB123667. Nine healthy male volunteers took a single, specially labeled oral dose so researchers could track it. The main goal was to measure how much of the d…